Form 4: Director Topper Plans NAMS Share Purchase Under 10b5-1

NewAmsterdam Pharma Director James N. Topper plans to acquire 1,260 ordinary shares at a weighted average price of $24.99 on September 8, 2025, under a 10b5-1 plan.

Summary

• James N. Topper, a Director and 10% owner of NewAmsterdam Pharma Co N.V. (NAMS), reported a planned acquisition of ordinary shares.
• The transaction is scheduled for September 8, 2025, and is being made pursuant to a Rule 10b5-1(c) trading plan.
• 1,260 ordinary shares are to be acquired at a weighted average price of $24.99 per share, with prices ranging from $24.86 to $25.00.
• The acquisition is being made indirectly through Frazier Life Sciences X, L.P.
• Following this planned transaction, indirect beneficial ownership through Frazier Life Sciences X, L.P. will be 3,027,864 shares, and through Frazier Lifesciences Sponsor LLC will be 3,801,000 shares.

Sentiment

Score: 7

Explanation: A director and 10% owner planning to purchase shares indicates confidence, even if the transaction is small and pre-scheduled. This is generally viewed as a positive signal for the company's future.

Positives

• A Director and 10% owner is planning to increase their stake in the company, which can be seen as a vote of confidence in future performance.
• The purchase is part of a pre-arranged trading plan under Rule 10b5-1(c), indicating a structured, non-discretionary transaction.

Future Outlook

The filing indicates a planned future acquisition of shares by a director, suggesting continued confidence in the company's long-term prospects, as the transaction is set for September 2025.

Management Comments

• The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Industry Context

Insider purchases, especially by directors and significant owners, are often viewed positively by the market as they signal management's belief in the company's future performance. This planned purchase by a 10% owner and Director of a pharmaceutical company could be interpreted as a positive signal for NewAmsterdam Pharma's drug development or market position.

Comparison to Industry Standards

• Insider buying activity is a common indicator tracked by investors. While the specific amount of shares planned for purchase (1,260) is relatively small compared to the total indirect holdings, the fact that a 10% owner and Director is planning to increase their stake, even modestly, can be seen as a positive signal. For example, similar planned purchases by executives at biotech firms like Moderna or Pfizer often precede positive news or strong financial performance, though this is not a guarantee.

Stakeholder Impact

• Shareholders may view the director's planned purchase as a positive indicator of future company performance, potentially boosting investor confidence.

Next Steps

• The planned acquisition of 1,260 ordinary shares is scheduled for September 8, 2025.

Key Dates

Recommendation

While the planned insider purchase by a director and 10% owner is a positive signal, the transaction size is relatively small (1,260 shares) compared to the total indirect holdings. It's a pre-scheduled 10b5-1 plan, which reduces the immediate discretionary signal. Investors should hold and monitor future developments, including the actual execution of this transaction and any further insider activity, alongside the company's operational and financial performance.

Keywords

NewAmsterdam Pharma, NAMS, Insider Trading, Form 4, Director Purchase, Share Acquisition, James N. Topper, 10b5-1 Plan, Frazier Life Sciences